中国病理生理杂志
中國病理生理雜誌
중국병리생리잡지
CHINESE JOURNAL OF PATHOPHYSIOLOGY
2009年
6期
1117-1121
,共5页
罗羽宏%梁忠平%李接兴%李震东
囉羽宏%樑忠平%李接興%李震東
라우굉%량충평%리접흥%리진동
胸腺肽α1%T淋巴细胞亚群%癌,肝细胞
胸腺肽α1%T淋巴細胞亞群%癌,肝細胞
흉선태α1%T림파세포아군%암,간세포
Thymosin alpha 1%T-lymphocyte subsets%Carcinoma,hepatocellular
目的:探讨肝癌患者术后早期应用胸腺肽α1对T淋巴细胞亚群的影响.方法:46例肝癌手术患者, 随机分治疗组(23例)和对照组(23例), 治疗组于术后1、3、5 d皮下注射胸腺肽α1 1 6 mg,观察2组术前后第1、4、7 d CD3+、CD4+、CD8+、CD4+/CD8+的变化情况.结果:(1)组内比较:对照组术后CD4+、CD4+/CD8+低于术前(P<0 05),术后第1、4、7 d CD8+高于手术前(P<0 05).治疗组CD3+、CD4+、 CD4+/CD8+术后与术前相比无显著差异;CD3+、CD4+/CD8+术后第1、7 d比较有显著差异(P<0 05).(2)组间比较:CD4+、CD4+/CD8+治疗组高于对照组(术后第1、4、7 d均P<0 05),治疗组CD8+细胞百分率低于对照组(术后第1、4、7 d均P<0 05);治疗组CD3+细胞百分率高于对照组(术后第4、7 d P<0 05).结论:手术对肝癌患者术后T淋巴细胞免疫功能有抑制作用,胸腺肽α1对T淋巴细胞免疫功能有调节作用.
目的:探討肝癌患者術後早期應用胸腺肽α1對T淋巴細胞亞群的影響.方法:46例肝癌手術患者, 隨機分治療組(23例)和對照組(23例), 治療組于術後1、3、5 d皮下註射胸腺肽α1 1 6 mg,觀察2組術前後第1、4、7 d CD3+、CD4+、CD8+、CD4+/CD8+的變化情況.結果:(1)組內比較:對照組術後CD4+、CD4+/CD8+低于術前(P<0 05),術後第1、4、7 d CD8+高于手術前(P<0 05).治療組CD3+、CD4+、 CD4+/CD8+術後與術前相比無顯著差異;CD3+、CD4+/CD8+術後第1、7 d比較有顯著差異(P<0 05).(2)組間比較:CD4+、CD4+/CD8+治療組高于對照組(術後第1、4、7 d均P<0 05),治療組CD8+細胞百分率低于對照組(術後第1、4、7 d均P<0 05);治療組CD3+細胞百分率高于對照組(術後第4、7 d P<0 05).結論:手術對肝癌患者術後T淋巴細胞免疫功能有抑製作用,胸腺肽α1對T淋巴細胞免疫功能有調節作用.
목적:탐토간암환자술후조기응용흉선태α1대T림파세포아군적영향.방법:46례간암수술환자, 수궤분치료조(23례)화대조조(23례), 치료조우술후1、3、5 d피하주사흉선태α1 1 6 mg,관찰2조술전후제1、4、7 d CD3+、CD4+、CD8+、CD4+/CD8+적변화정황.결과:(1)조내비교:대조조술후CD4+、CD4+/CD8+저우술전(P<0 05),술후제1、4、7 d CD8+고우수술전(P<0 05).치료조CD3+、CD4+、 CD4+/CD8+술후여술전상비무현저차이;CD3+、CD4+/CD8+술후제1、7 d비교유현저차이(P<0 05).(2)조간비교:CD4+、CD4+/CD8+치료조고우대조조(술후제1、4、7 d균P<0 05),치료조CD8+세포백분솔저우대조조(술후제1、4、7 d균P<0 05);치료조CD3+세포백분솔고우대조조(술후제4、7 d P<0 05).결론:수술대간암환자술후T림파세포면역공능유억제작용,흉선태α1대T림파세포면역공능유조절작용.
AIM: To investigate the effects of early application of thymosin peptide alpha 1 on lymphocyte subsets after operation in patients with hepatocellular carcinoma. METHODS: Forty-six patients with hepatocellular carcinoma were randomly divided into control and treatment groups for this study. Thymosin α1 at dose of 1.6 mg was injected subcutaneously on day 1, 3, and 5 after operation in treatment group. The percentages of CD3+, CD4+ and CD8+ cells, and CD4+/CD8+ ratio in both groups were counted before operation and on day 1, 4, and 7 after hepatectomy. RESULTS: CD4+ cell population and CD4+/CD8+ ratio decreased, but CD8+ increased after operation in control group (P<0 05). In thymosin peptide alpha 1 treatment group, there was no statistical difference in the percentages of CD3+, CD4+, CD8+, and CD4+/CD8+ before and after operation. In addition, thymosin α1 significantly increased CD4+ cell population and CD4+/CD8+ ratio (P<0 05). CONCLUSION: Operation suppresses the immune function in patients with hepatocellular carcinoma. Thymosin α1 increases CD4+ T lymphocyte subsets in patients after operation.